易瑞生物
(300942)
| 流通市值：39.25亿 | | | 总市值：39.25亿 |
| 流通股本：4.01亿 | | | 总股本：4.01亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 419,229,213.25 | 293,399,311.14 | 250,473,992.19 | 386,556,002.12 |
| 衍生金融资产 | 237,652.07 | - | - | 22,400 |
| 应收票据及应收账款 | 81,780,518.1 | 94,108,738.25 | 83,046,309.89 | 77,567,800.59 |
| 其中：应收票据 | 31,055 | 50,000 | - | - |
| 应收账款 | 81,749,463.1 | 94,058,738.25 | 83,046,309.89 | 77,567,800.59 |
| 应收款项融资 | - | - | 555,040 | 590,508 |
| 预付款项 | 8,425,836.26 | 4,905,642.34 | 12,322,871.72 | 12,727,002.56 |
| 其他应收款合计 | 4,729,840.96 | 5,799,009.22 | 9,683,332.13 | 12,648,548.7 |
| 存货 | 40,907,172.43 | 40,430,062.74 | 38,721,089.74 | 41,045,392.47 |
| 其他流动资产 | 13,348,878.35 | 10,058,204.33 | 6,953,363.59 | 6,961,142.91 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 730,932,473.54 | 751,616,151.89 | 733,305,067.2 | 775,474,440.24 |
| 非流动资产: | | | | |
| 长期股权投资 | 99,961,461 | 100,689,968.41 | 102,995,728.85 | 106,770,514.75 |
| 固定资产 | 358,753,842.93 | 363,111,336.95 | 50,659,738.5 | 52,994,500.2 |
| 在建工程 | 211,091,768.42 | 199,792,641.95 | 448,136,399.09 | 413,142,412.69 |
| 使用权资产 | - | - | - | 339,301.31 |
| 无形资产 | 38,757,730.11 | 39,243,012.99 | 39,712,682.1 | 40,183,192.35 |
| 长期待摊费用 | 1,740,940.48 | 1,676,331.65 | 570,155.97 | 621,087.6 |
| 递延所得税资产 | 879,976.78 | 79,078.8 | 1,378,015.96 | 2,352,695.4 |
| 其他非流动资产 | 957,413.28 | 957,413.28 | 1,999,417.83 | 2,277,300.7 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 712,143,133 | 705,549,784.03 | 645,452,138.3 | 618,681,005 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 1,443,075,606.54 | 1,457,165,935.92 | 1,378,757,205.5 | 1,394,155,445.24 |
| 流动负债: | | | | |
| 衍生金融负债 | 0 | 34,645.41 | - | 242,730.56 |
| 应付票据及应付账款 | 51,219,299.39 | 58,762,442.61 | 62,116,123.89 | 75,270,370.44 |
| 应付账款 | 51,219,299.39 | 58,762,442.61 | 62,116,123.89 | 75,270,370.44 |
| 预收款项 | 955,551.92 | 109,647.69 | - | - |
| 合同负债 | 19,356,363.94 | 24,992,820.15 | 18,219,449.06 | 18,396,323.59 |
| 应付职工薪酬 | 12,695,672.67 | 18,699,553.31 | 19,359,344.63 | 17,291,030.97 |
| 应交税费 | 2,576,004.67 | 790,691.67 | 578,329.46 | 413,414.19 |
| 其他应付款合计 | 3,796,243.69 | 4,423,186.14 | 2,000,746.61 | 5,573,624.14 |
| 一年内到期的非流动负债 | 40,618,945.61 | 41,598,111.04 | 37,671,628.55 | 39,707,699.6 |
| 其他流动负债 | 2,479,485.46 | 2,546,642.23 | 1,756,177.87 | 1,639,406.72 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 133,697,567.35 | 151,957,740.25 | 141,701,800.07 | 158,534,600.21 |
| 非流动负债: | | | | |
| 长期借款 | 166,482,190.93 | 163,217,749.82 | 111,346,175.35 | 112,663,307.06 |
| 应付债券 | 268,456,594.89 | 263,168,579.26 | 260,605,117.77 | 255,510,044.65 |
| 预计负债 | 2,080,000 | 2,080,000 | 2,080,000 | 2,080,000 |
| 递延收益 | 6,010,896.22 | 6,499,295.61 | 9,308,219.16 | 16,543,139.68 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 443,029,682.04 | 434,965,624.69 | 383,339,512.28 | 386,796,491.39 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 576,727,249.39 | 586,923,364.94 | 525,041,312.35 | 545,331,091.6 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 401,317,397 | 401,316,667 | 400,866,877 | 400,865,232 |
| 其他权益工具 | 68,386,319.97 | 68,387,934.52 | 69,381,109.57 | 69,386,376.65 |
| 资本公积 | 190,220,990.47 | 190,215,233.93 | 186,670,479.43 | 186,651,984.94 |
| 其他综合收益 | 38,858.13 | -55,803.95 | 51,067.66 | 114,455 |
| 盈余公积 | 55,512,481.54 | 55,512,481.54 | 53,580,647.83 | 53,580,647.83 |
| 未分配利润 | 150,282,821.49 | 153,628,825.18 | 142,341,101.45 | 136,884,636.39 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 865,758,868.6 | 869,005,338.22 | 852,891,282.94 | 847,483,332.81 |
| 少数股东权益 | 589,488.55 | 1,237,232.76 | 824,610.21 | 1,341,020.83 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 866,348,357.15 | 870,242,570.98 | 853,715,893.15 | 848,824,353.64 |
| 负债和股东权益合计 | 1,443,075,606.54 | 1,457,165,935.92 | 1,378,757,205.5 | 1,394,155,445.24 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |